During the past decade, Instituto DAMIC - Fundacion Rusculleda conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 6 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 5 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto DAMIC - Fundacion Rusculleda" #1 sponsor was "R-Pharm International, LLC" with 3 trials, followed by "Boehringer Ingelheim" with 1 trials sponsored, "Celgene" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto DAMIC - Fundacion Rusculleda" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator and "Mene Research" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Instituto DAMIC - Fundacion Rusculleda" are "Rheumatoid Arthritis" (3 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Diabetes Mellitus, Type 2" (1 trials), "Metastatic Breast Cancer" (1 trials) and "Schizophrenia" (1 trials). Many other conditions were trialed in "Instituto DAMIC - Fundacion Rusculleda" in a lesser frequency.

Most popular intervention types in "Instituto DAMIC - Fundacion Rusculleda" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Adalimumab 40mg q2w" (1 trials), "Antipshychotics (Standard of Care)" (1 trials), "Avelumab" (1 trials) and "Concomitant treatment" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instituto DAMIC - Fundacion Rusculleda" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Instituto DAMIC - Fundacion Rusculleda". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Instituto DAMIC - Fundacion Rusculleda, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto DAMIC - Fundacion Rusculleda, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".